WO2011153590A8 - Use of interferon epsilon in methods of diagnosis and treatment - Google Patents

Use of interferon epsilon in methods of diagnosis and treatment Download PDF

Info

Publication number
WO2011153590A8
WO2011153590A8 PCT/AU2011/000715 AU2011000715W WO2011153590A8 WO 2011153590 A8 WO2011153590 A8 WO 2011153590A8 AU 2011000715 W AU2011000715 W AU 2011000715W WO 2011153590 A8 WO2011153590 A8 WO 2011153590A8
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
diagnosis
treatment
methods
predisposition
Prior art date
Application number
PCT/AU2011/000715
Other languages
French (fr)
Other versions
WO2011153590A1 (en
Inventor
Paul Hertzog
Helen Cummung
Sebastian Sifter
Ka Yee Fung
Niamh Mangan
Nicole De Weerd
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010902537A external-priority patent/AU2010902537A0/en
Application filed by Monash University filed Critical Monash University
Publication of WO2011153590A1 publication Critical patent/WO2011153590A1/en
Publication of WO2011153590A8 publication Critical patent/WO2011153590A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates generally to a method of diagnosing, predicting and/or monitoring the predisposition of a female mammal to reproductive tract infection by a pathogen. More particularly, the present invention relates to a method of diagnosing, predicting and/or monitoring the predisposition of a female mammal to reproductive tract infection by a pathogen by analysing IFNe levels either in said mammal or in a biological sample derived from said mammal. The present invention further provides a method of predicting, diagnosing and/or monitoring the predisposition of a female mammal to conditions associated with or characterised by infection of the reproductive tract with a pathogen.
PCT/AU2011/000715 2010-06-09 2011-06-09 Use of interferon epsilon in methods of diagnosis and treatment WO2011153590A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010902537 2010-06-09
AU2010902537A AU2010902537A0 (en) 2010-06-09 A method of diagnosis and treatment

Publications (2)

Publication Number Publication Date
WO2011153590A1 WO2011153590A1 (en) 2011-12-15
WO2011153590A8 true WO2011153590A8 (en) 2012-01-12

Family

ID=45097405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2011/000715 WO2011153590A1 (en) 2010-06-09 2011-06-09 Use of interferon epsilon in methods of diagnosis and treatment

Country Status (1)

Country Link
WO (1) WO2011153590A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117442733B (en) * 2023-12-25 2024-03-29 南方医科大学 Application of IRF7 expression inhibitor in preparation of medicine for preventing and treating reproduction toxicity caused by 1,2-dichloroethane

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142061A0 (en) * 1998-09-18 2002-03-10 Zymogenetics Inc Interferon-epsilon

Also Published As

Publication number Publication date
WO2011153590A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
WO2011135194A3 (en) Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes
WO2012110878A3 (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
WO2011107482A3 (en) Method of diagnostic of obesity
IL222252A (en) System, assembly and method for the detection and diagnosis of biological rhythm disorders
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
WO2012018535A3 (en) Wellness panel
WO2011106536A3 (en) Methods of diagnosing infectious disease pathogens and their drug sensitivity
WO2012012693A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2012061836A3 (en) Improved algorithm for detection of diabetes
WO2012006208A3 (en) Method and/or system for determining blood glucose reference sample times
WO2012021407A3 (en) Biomarkers for stroke
EP2291400A4 (en) Method of diagnosis of infection by mycobacteria and reagents therefor
WO2011142827A3 (en) Diagnostic markers for neuropsychiatric disease
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
WO2012054783A3 (en) Internal focus reference beads for imaging cytometry
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
AU2012339149A8 (en) Method for the diagnosis of Niemann-Pick disease
EP2660310A4 (en) Comprehensive glaucoma determination method utilizing glaucoma diagnosis chip and deformed proteomics cluster analysis
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
EP3839068A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2010144553A3 (en) Methods for diagnosing blood vessel reocclusion
WO2012004276A3 (en) Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
WO2012074882A3 (en) Phagocytic activity as a marker of synucleinopathic disease
WO2012169887A3 (en) Use of new markers in a diagnostic assay for determining severity of rsv infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11791753

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11791753

Country of ref document: EP

Kind code of ref document: A1